For instance, favorable outcomes are reported from combining venetoclax with hypomethylating agents, especially in NPM1-mutated cases [36] or ivosidenib with azacytidine in IDH1-mutated AML [37]. This evidence concerns the gene IDH1 and acute myeloid leukemia.